CA2232390A1 - Chimiotherapie par les oligonucleotides antisens de l'hyperplasie ou du cancer de la prostate - Google Patents

Chimiotherapie par les oligonucleotides antisens de l'hyperplasie ou du cancer de la prostate Download PDF

Info

Publication number
CA2232390A1
CA2232390A1 CA 2232390 CA2232390A CA2232390A1 CA 2232390 A1 CA2232390 A1 CA 2232390A1 CA 2232390 CA2232390 CA 2232390 CA 2232390 A CA2232390 A CA 2232390A CA 2232390 A1 CA2232390 A1 CA 2232390A1
Authority
CA
Canada
Prior art keywords
oligonucleotides
oligonucleotide
seq
group
consecutive bases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2232390
Other languages
English (en)
Inventor
Paul A. Zamecnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
University of Massachusetts UMass
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Massachusetts UMass filed Critical University of Massachusetts UMass
Publication of CA2232390A1 publication Critical patent/CA2232390A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11012—Linoleate 13S-lipoxygenase (1.13.11.12)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un procédé sélectif inhibant la croissance des cellules prostatiques ou les tuant à l'aide d'oligonucléotides antisens de gènes spécifiques de la prostate. Lesdits oligonucléotides peuvent présenter la structure d'acides nucléiques naturels ou d'oligonucléosides modifiés à stabilité renforcée ou ciblant des tissus spécifiques. Les gènes spécifiques de la prostate vers lesquels les antisens peuvent être dirigés comportent les gènes PSA et de la probasine. Elle porte également sur des préparations pharmaceutiques comprenant lesdits oligonucléotides antisens utilisées dans ces procédés. Lesdits procédés et produits s'avèrent notamment utiles pour le traitement de l'hyperplasie prostatique bénigne du cancer de la prostate.
CA 2232390 1995-09-20 1996-09-20 Chimiotherapie par les oligonucleotides antisens de l'hyperplasie ou du cancer de la prostate Abandoned CA2232390A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US404495P 1995-09-20 1995-09-20
US60/004,044 1995-09-20

Publications (1)

Publication Number Publication Date
CA2232390A1 true CA2232390A1 (fr) 1997-03-27

Family

ID=21708853

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2232390 Abandoned CA2232390A1 (fr) 1995-09-20 1996-09-20 Chimiotherapie par les oligonucleotides antisens de l'hyperplasie ou du cancer de la prostate

Country Status (4)

Country Link
EP (1) EP0856052A1 (fr)
AU (1) AU7077596A (fr)
CA (1) CA2232390A1 (fr)
WO (1) WO1997011172A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100444A (en) * 1997-02-11 2000-08-08 University Of Rochester Medical Center Prostate specific regulatory nucleic acid sequences and transgenic non-human animals expressing prostate specific antigen
JP2002516261A (ja) * 1998-05-22 2002-06-04 エンターメッド インコーポレイテッド セリンプロテアーゼを利用して内皮細胞増殖を阻害し血管新生を調節するための組成物と方法
US6413513B1 (en) 1998-05-22 2002-07-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
EP0652014A1 (fr) * 1993-11-10 1995-05-10 National Institute Of Immunology Traitement d'hypertrophie prostatique
US6468981B1 (en) * 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors

Also Published As

Publication number Publication date
AU7077596A (en) 1997-04-09
WO1997011172A1 (fr) 1997-03-27
EP0856052A1 (fr) 1998-08-05

Similar Documents

Publication Publication Date Title
US5734039A (en) Antisense oligonucleotides targeting cooperating oncogenes
US5618709A (en) Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
US5747470A (en) Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
US5783683A (en) Antisense oligonucleotides which reduce expression of the FGFRI gene
EP0690726B1 (fr) Inhibition antisens du proto-oncogene c-myc permettant de moduler la proliferation des cellules des muscles lisses
US7846907B2 (en) Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene
US5652222A (en) Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
JPH10508760A (ja) ｒａｆ遺伝子発現のアンチセンスオリゴヌクレオチド調節
JPH09507381A (ja) 血管平滑筋細胞の増殖の阻害
JP2003500052A (ja) ヒストン脱アセチル酵素の抑制
CA2239976A1 (fr) Chimiotherapie par oligonucleotides antisens de l'hypertrophie ou du cancer de la prostate
KR20010102943A (ko) 결합 조직 성장 인자(ｃｔｇｆ) 및 그의 이용 방법
CA2105595A1 (fr) Polynucleotides antisens
JP2002512508A (ja) Ｄｎａメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド
JPH08506087A (ja) ガン処置のための抗腫瘍薬とアンチセンスオリゴヌクレオチドの組み合わせ
CA2232724A1 (fr) Oligonucleotides modifiees specifiques de la proteine kinase a et leurs modes d'utilisation
Ho et al. Antisense oligonucleotides selectively regulate aspartyl β-hydroxylase and its truncated protein isoform in vitro but distribute poorly into A549 tumors in vivo
CA2232390A1 (fr) Chimiotherapie par les oligonucleotides antisens de l'hyperplasie ou du cancer de la prostate
WO2009003211A1 (fr) Traitement de la polyarthrite rhumatoïde
WO1995024223A1 (fr) Inhibition de la proliferation cellulaire par des oligonucleotides non codants specifiques contre e2f-1
US5935937A (en) Compositions and methods for inducing apoptosis
CA2223109A1 (fr) Utilisation d'oligonucleotides antisens complementaires de l'arnm du recepteur de l'interleukine-6 pour inhiber la proliferation cellulaire
US5872007A (en) CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer
Ma et al. Recent status of the antisense oligonucleotide approaches in oncology
JPH07501525A (ja) ｃ−ｍｙｂプロトオンコジーンに対するアンチセンスオリゴヌクレオチドによる黒色腫の処置

Legal Events

Date Code Title Description
FZDE Dead